Literature DB >> 19352049

Endothelial dysfunction is related to aldosterone excess and raised blood pressure.

Kyoichiro Tsuchiya1, Takanobu Yoshimoto, Yukio Hirata.   

Abstract

Primary aldosteronism (PA) is a secondary hypertension characterized by autonomous aldosterone hypersecretion from adrenocortical adenoma and/or hyperplasia. Recently it has been suggested that aldosterone excess is directly involved in the development of cardiovascular injury in PA independent of its hypertensive effect. The present study was designed to examine the relationship between aldosterone excess and endothelial dysfunction in PA patients. 25 PA patients were studied for vascular endothelial function by ultrasound measurement of flow-mediated vasodilation (FMD), and 10 PA patients were re-evaluated 3 months after surgical or medical treatment; 10 age-, gender-, and blood pressurematched hypertensive patients served as control subjects. Percent (%) FMD in PA patients (4.6+/-2.0%) was significantly (p < 0.0001) lower than that in the control subjects (7.9+/-2.0%). %FMD showed significant (p < 0.05) negative correlations with systolic blood pressure (SBP) (r=-0.48), brachial-ankle pulse wave velocity (r=-0.52), plasma aldosterone concentration (PAC) (r=-0.42), and aldosterone-renin ratio (ARR) (r=-0.42), while SBP showed a positive correlation with PAC (r=0.47). Percent FMD, SBP, PAC, and ARR significantly (p < 0.05) improved after surgical and medical treatment, although the changes of %FMD did not correlate with those of SBP, PAC or ARR. In conclusion, the present study has demonstrated that PA patients have endothelial dysfunction, which is related to aldosterone excess and raised blood pressure, and reversible after treatment, suggesting that aldosterone excess contributes to the development of endothelial dysfunction due to its hypertensive effect and/or its direct effect on the cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19352049     DOI: 10.1507/endocrj.k09e-014

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  11 in total

Review 1.  Vascular endothelial function and hypertension: insights and directions.

Authors:  Kodlipet Dharmashankar; Michael E Widlansky
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

Review 2.  Treatment of primary aldosteronism: Where are we now?

Authors:  Asterios Karagiannis
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

3.  Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage.

Authors:  G Liu; G-S Yin; J-y Tang; D-J Ma; J Ru; X-H Huang
Journal:  J Hum Hypertens       Date:  2014-02-20       Impact factor: 3.012

Review 4.  Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications.

Authors:  Noboru Toda; Sadanobu Nakanishi; Shinichi Tanabe
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

5.  Aldosteronism and resistant hypertension.

Authors:  Maria Czarina Acelajado; David A Calhoun
Journal:  Int J Hypertens       Date:  2011-01-20       Impact factor: 2.420

6.  Hypertension with primary aldosteronism is associated with increased carotid intima-media thickness and endothelial dysfunction.

Authors:  Ahmet Demirkiran; Henk Everaars; Ali Elitok; Peter M van de Ven; Yvo M Smulders; Koen M Dreijerink; Refik Tanakol; Mustafa Ozcan
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-12       Impact factor: 3.738

7.  Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension.

Authors:  Miaomiao Sang; Yu Fu; Chenmin Wei; Jing Yang; Xueting Qiu; Jingqing Ma; Chao Qin; Feiyan Wu; Xueling Zhou; Tao Yang; Min Sun
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021 Jan-Dec       Impact factor: 1.636

8.  Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.

Authors:  Che-Wei Liao; Lian-Yu Lin; Chi-Sheng Hung; Yen-Tin Lin; Yi-Yao Chang; Shuo-Meng Wang; Vin-Cent Wu; Kwan-Dun Wu; Yi-Lwun Ho; Fumitoshi Satoh; Yen-Hung Lin
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

9.  Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.

Authors:  Silvia Lai; Luigi Petramala; Daniela Mastroluca; Emanuela Petraglia; Alessandro Di Gaeta; Elena Indino; Valeria Panebianco; Mauro Ciccariello; Hossein H Shahabadi; Alessandro Galani; Claudio Letizia; Anna Rita D'Angelo
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

10.  Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism.

Authors:  Daisuke Watanabe; Satoshi Morimoto; Noriko Morishima; Atsuhiro Ichihara
Journal:  Endocr Connect       Date:  2021-06-08       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.